NewsRoom Articles - Page 87 of 154 - PsychedelicNewsWire (PNW)

TuesdayAug 24, 2021 2:15 pm

Four Fungi Facts Revealed by Netflix Psychedelics Documentary

Psychedelics have become increasingly popular in the last few years as more studies on the substances are conducted by research institutions around the world. The most popular of these substances are LSD, MDMA and psilocybin mushrooms. If you’re yearning to know more about these substances and mushrooms and other fungi in general, but aren’t keen on reading papers in peer review journals, Netflix may be of use to you. The subscription-based streaming service has a documentary, titled “Fantastic Fungi.” that talks about different fungi, The documentary reveals interesting things about mushrooms, some of which aren’t commonly known. For instance, did…

MondayAug 23, 2021 3:30 pm

Five Medical Benefits of Psychedelics

Research on psychedelics has found that the substances could be effectively used to treat various mental health conditions, including post-traumatic stress disorder and anxiety. But, what other therapeutic and medical benefits do psychedelics possess that may help humanity? Making organ transplants safer Ischemia-reperfusion injury, commonly referred to as IRI, occurs when organ tissues are damaged after being deprived of oxygen for some time. The inury can affect organs such as the brain, kidneys, lungs and the heart, and it mainly plagues patients who have undergone organ transplants. Physicians use machine perfusion and ischemic pre- and post-conditioning to reduce or prevent…

MondayAug 23, 2021 10:44 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter,…

FridayAug 20, 2021 2:00 pm

Salvia Divinorum: The Less-Known Psychedelic and Its Properties

The popularity of psychedelics has been growing as the research conducted on these substances for their therapeutic benefits increases. Substances such as DMT, LSD, MDMA and psilocybin are the most studied as well as the most common psychedelics while others, including salvia divinorum, aren’t popularly known. Salvia divinorum is a psychoactive plant used in rituals in Mazatec shamanic ceremonies. The plant species is found in the mountainous Sierra Mazateca area near Mexico’s Oaxaca City. Its leaves contain a compound known as salvinorin A, which induces the plant’s psychoactive effects when the leaves are smoked or chewed. This compound’s presence hinders…

ThursdayAug 19, 2021 2:30 pm

Florida Researchers Seek Answers on Ability of Psychedelics to Treat Psychological Conditions

Research on psychedelic substances and the therapeutic properties they possess that can be used to treat various mental health conditions has been increasing. For example, researchers in Florida are focused on studying psilocybin, which is the active compound found in magic mushrooms. Earlier in 2019, the FDA granted breakthrough therapy status to psilocybin treatments under development, which made it easier for the Usona Institute, a nonprofit organization, to conduct studies on the psychedelic. Dr. Charles Raison, the institute’s director of clinical and translational research, stated that the organization had sites in seven states and was planning to establish a duo…

ThursdayAug 19, 2021 11:56 am

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’

Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research The Vancouver-based company was formed in 2019 as the ‎first psychedelic umbrella platform The Delic self-sustaining Ecosystem covers three main areas: media, health, and science On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company, a legacy counterculture distributor of psychedelic media An estimated $238 billion is spent annually in the U.S. on mental health treatments and ancillary services University-led and FDA-approved studies are positioning North America as a leading region in the advancement…

ThursdayAug 19, 2021 11:23 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Cybin subsidiary achieved certain milestones as outlined in acquisition agreement Adelia brought numerous advantages to company Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin's (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain milestones for the year as outlined in the acquisition agreement, resulting in Adelia shareholders receiving common shares in Cybin. Cybin closed on the acquisition of Adelia late last year, with the company noting…

ThursdayAug 19, 2021 10:59 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials

Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies Calvert Labs shall perform TRP-8803 and TRP-8802 are psilocybin-based products being evaluated under Tryp’s PFN program Tryp intends to use TRP-8802 in the Phase 2a clinical trials, while TRP-8803 will be used in Phase 2b clinical trials and beyond The San Diego-based pharmaceutical company, Tryp…

WednesdayAug 18, 2021 1:45 pm

Praying, Using Psychedelic Substances May Activate Similar Regions in Brain

Prayer and psychedelic substances have both demonstrated that they have antidepressant, analgesic and anxiolytic properties. This is in addition to showing that they can both induce alterations of mood and perception. Various studies using functional magnetic resonance imaging have identified cortical regions and brain structures that become active when individuals undergo intense spiritual experiences or are exposed to various psychedelic substances. Spiritual retreat participants usually report enhanced spiritual well-being or improved sense of spirituality, which researchers think may be linked to changes in functional connectivity between regions in the brain that were actively involved in the production of those feelings.…

TuesdayAug 17, 2021 1:20 pm

New Poll Suggests 80% of Canadians Support Legalization of Psilocybin for Medical Use

A recent survey reported that four out of every five Canadians are in favor of the therapeutic use of psilocybin for individuals who suffer from a terminal condition; those respondents urge the government to establish a regulatory framework to allow its use in these circumstances. The poll was carried out by Nanos Research and commissioned by the Canadian Psychedelic Association (“CPA”). For the survey, more than 1,000 Canadian adults were interviewed between June 30, 2021, and July 5, 2021. More than 75% of the survey’s respondents stated that they supported the establishment of a legal regulatory model to facilitate the…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000